supraclavicular lymph nodes swollen right side

All patients underwent esophagectomy with three-field lymph node dissection. One hundred sixty-three patients with thoracic esophageal squamous cancer (ESCC) who were diagnosed by pathological examination in the Affiliated Hospital of Jiangnan University and Affiliated Cancer Hospital of Nanjing Medical University from January 1, 2014, to December 31, 2017, were included. To this end, we conducted a retrospective clinical study to evaluate the survival benefit of dissection of metastases to the SCLNs in different segmental thoracic esophageal cancer. However, they did not have a multivariate analysis of the prognosis of different segmental thoracic esophageal cancer. They believed SCLNs appear to be regional nodes like other regional nodes. Multivariate analysis showed that SCLNs metastasis was not an independent risk factor for postoperative survival of thoracic esophageal cancer (P=0.062). The 5-year survival was 73.7% for patients with N0, 40.4% for node-positive patients without SCLNs disease, and 24.1% for patients with SCLNs metastasis. ( 7) founded that 190 (14.5%) had SCLNs metastases. In a study involving 1,309 cases of esophageal cancer, Tachimori et al. Therefore, whether there is a need for SCLNs dissection for thoracic esophageal cancer is still controversial ( 5, 6). Many clinicians believe that distant metastatic lesions should not be treated surgically, but some studies have shown that patients with SCLNs metastases have a better prognosis than other organs metastases ( 3, 4). However, the supraclavicular lymph nodes (SCLNs) remain as distant metastases (M1). The eighth edition of UICC and AJCC esophageal cancer TNM staging indicates that regardless of the location of the primary tumor, celiac axis nodes and paraesophageal nodes in the neck are included in the regional lymph nodes. Lymph node metastasis is an important factor affecting the prognosis of esophageal cancer ( 1, 2). Keywords: Supraclavicular lymph nodes (SCLNs) thoracic esophageal squamous cancer (thoracic ESCC) complications prognosis For the middle and lower thoracic ESCC, SCLNs should be defined as distant metastasis, and neoadjuvant therapy first may be an available therapy. Multivariate analysis found that SCLNs metastasis was an independent risk factor affecting the prognosis of ESCC in the middle and lower thoracic segments (P=0.007).Ĭonclusions: For patients with upper thoracic ESCC, SCLNs appear to be regional nodes. In the upper thoracic group, there was no significant difference in OS between SCLNs positive group and negative group (P=0.077) however, in the middle and lower thoracic group, SCLNs positive group had a worse prognosis than the negative group (P<0.001) and lymph nodes positive in other sites (except for SCLNs) (P=0.039). Results: Patients with SCLNs metastasis had a worse prognosis than the negative group (P<0.001). Methods: Retrospectively collected the clinical data of 163 patients with thoracic esophageal squamous cancer (ESCC) and compared the effects of SCLNs on prognosis in different segments. In this study, we aimed to analyze the prognosis of SCLNs on the different segments of thoracic esophageal cancer, which will supply a reference for the treatment of this disease. Policy of Dealing with Allegations of Research Misconductīackground: Although most studies proved that thoracic esophageal cancer surgery with supraclavicular lymph nodes (SCLNs) metastasis could benefit, less than 30% of the 5-year survival rate remained controversy on its surgical treatment.Policy of Screening for Plagiarism Process.

Supraclavicular lymph nodes swollen right side